BioAtla (BCAB) Price to Sales (2021 - 2026)

BioAtla's (BCAB) quarterly Price to Sales came in at 1.06 in Q2 2026, down 99.88% quarter-over-quarter from 900.72 in Q4 2025.

Analysis

BioAtla (BCAB) Price to Sales (2021 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Price to Sales for 4 consecutive years, with 1.06 the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Price to Sales changed N/A year-over-year to 1.06; the trailing twelve-month figure through Jun 2026 stood at 0.81 (down 99.23% YoY), and the FY2025 full-year result was 900.72, up 476.91% from the prior year.
Price to Sales fell to 1.06 in Q2 2026 per BCAB's latest filing, from 900.72 in the prior quarter.
Across five years, Price to Sales topped out at 900.72 in Q4 2025 and bottomed at 1.06 in Q2 2026.
Historically, Price to Sales has averaged 429.51 across 3 years, with a median of 386.76 in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	209.95 Bn	195.96 Bn	7.24 Bn
2	Gilead Sciences	180.35 Bn	177.17 Bn	6.22 Bn
3	Vertex Pharmaceuticals	132.26 Bn	124.41 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	82.62 Bn	74.62 Bn	3.93 Bn
5	Argenx Se	61.19 Bn	56.00 Bn	1.37 Bn
6	Moderna	53.61 Bn	48.47 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	33.75 Bn	30.44 Bn	992.69 Mn
8	Biogen	31.58 Bn	30.30 Bn	1.96 Bn
9	Roivant Sciences	29.42 Bn	29.42 Bn	1.16 Mn
10	BioAtla	2.33 Mn	2.33 Mn	-

Historic Data

Download Data